Displaying 1 - 20 of 53
| Active Ingredient | CARDIOVASCULAR DRUGS |
| Therapeutic Class | CARDIOVASCULAR DRUGS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | CARDIAC DRUGS |
| Therapeutic Class | CARDIAC DRUGS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | ADENOSINE |
| Therapeutic Class | ANTIARRHYTHMIC AGENTS |
| Indications | Rapid reversion to sinus rhythm of paroxysmal supraventricular tachycardias. |
| Caution | Nausea, lightheadedness, flushing, headache, angina-like chest pain, apprehension, and dyspnea. |
| Dose Range |
Initial dose of 3 mg by rap id intravenous injection, if this dose is not effective within 1 to 2 minutes, 6 mg may be given and if necessary , 12 mg after a further 1 to 2 minutes. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | AMIODARONE |
| Therapeutic Class | ANTIARRHYTHMIC AGENTS |
| Indications | Effective for the treatment of life-threatening recurrent ventricular fibrillation and tachycardia that has been unresponsive to other antiarrhythmic agents. It is also effective for recurrent and/or More ... |
| Caution | Severe toxicity , exacerbation of arrhythmias, bradycardia, hypotension, congestive heart failure, cardiac arrest, pulmonary toxicity , hepatotoxicity, hypo- or hyperthyroidism, nausea, vomiting,con More ... |
| Dose Range | Adult: 200mg 3 times a day for 1 week, then 200mg twice daily for 1 week, then a usual maintenance dose of 200mg or less daily . Pediatric: loading dose of 10-20 mg/kg daily (or 500 mg/m2 daily ) for 7 to 10 days, followed by the lowest possible |
| Drug Interactions | |
| Pregnancy | Amiodarone may cause fetal harm when administered to a pregnant woman. IV amioda More ... |
| Breast Feeding | Amiodarone is distributed in breastmilk and is not recommended for lactating wom More ... |
| Active Ingredient | FLECAINIDE |
| Therapeutic Class | ANTIARRHYTHMIC AGENTS |
| Indications | Supraventricular arrhythmias, ventricular arrhythmias. |
| Caution | Dizziness, visual disturbances, fatigue, and lightheadedness. |
| Dose Range | Adult: Supraventricular arrhythmias: Initially 50 mg twice daily , increased if necessary up to 300 mg daily. Ventricular arrhythmias: Initially 100 mg twice daily for 3-5 days, maximum 400 mg daily reserved for rapid control or in heavily built patien |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | PROCAINAMIDE |
| Therapeutic Class | ANTIARRHYTHMIC AGENTS |
| Indications | A class IA antiarrhythmic used for the short -term management ofsevere or symptomatic ventricular arrhythmias. |
| Caution | Hypotension, nausea, vomiting, diarrhoea, giddiness, mental depression. With long term use- SLE type syndrome, agranulocytosis(rarely ). Regular antinucleofactor (ANF) testing should be done on p More ... |
| Dose Range | Oral: 500mg - 1g stat, then 250mg -1g every 6 hours. Inj: 1mg/min i.v to a maximum of 10mg. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding | Procainamide is distributed in breastmilk and not recommended for lactating wome More ... |
| Active Ingredient | PROPAFENONE |
| Therapeutic Class | ANTIARRHYTHMIC AGENTS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | TRIMETAZIDINE |
| Therapeutic Class | ANTIARRHYTHMIC AGENTS |
| Indications | Second-line add-on therapy in the treatment of stable angina pectoris. |
| Caution | Parkinsonian symptoms, restless legs syndrome, tremor, and abnormal gait. Use with caution in the elderly and in renal or hepatic insufficiency .Therapy should be stopped permanently in patients who More ... |
| Dose Range | 40-60mg daily in divided doses. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | DIGOXIN |
| Therapeutic Class | CARDIAC GLYCOSIDES |
| Indications | Cardiac failure, atrial fibrillation, atrial flutter, paroxysmal tachycardia. |
| Caution |
Nausea, vomiting, arrhythmias, heart block. Also see information on cardiac glycosides on page 213. c.f. prescribing in renal disease p. 28. Thiazide & Loop diuretics & corticosteroids reduce blood [K More ... |
| Dose Range |
Adult and children 10 years and over: Oral rapid digitalization: 0.75-1.5mg in divided doses over a 24 hour period. Maintenance: 0.25-0.5mg daily. Paediatric: Initially 25-45mcg/kg in 3 divided doses over 24 hours then 4-10 mcg/kg daily. |
| Drug Interactions | |
| Pregnancy | Digoxin crosses the placenta and can be detected in the fetus. Dosage adjusments More ... |
| Breast Feeding | Digoxin is distributed in breastmilk. Use with caution in lactating women. |
| Active Ingredient | MILRINONE LACTATE |
| Therapeutic Class | CARDIOTONIC AGENTS |
| Indications | Short-term treatment of severe congestive heart failure unresponsive to conventional maintenance therapy; acute heart failure after cardiac surgery . |
| Caution | Monitor renal function. Ectopic beats, ventricular tachycardia, supraventricular arrhythmias, hypotension, headache. |
| Dose Range | Intravenous injection over 10 minutes, either undiluted or diluted before use, 50 micrograms/kg followed by intravenous infusion at a rate of 375-75 nanograms/kg/minute, usually for up to 12 hours following surgery or for 48-72 hours in congesti |
| Drug Interactions | |
| Pregnancy | Manufacturer advises use only if potential benefit outweighs risk. |
| Breast Feeding | Use milrinone with caution in lactating women. |
| Active Ingredient | IVABRADINE |
| Therapeutic Class | CARDIAC DRUGS MISCELLANEOUS |
| Indications | Stable angina pectoris,mild to severe chronic heart failure. |
| Caution |
Atrial fibrillation; blurred vision; bradycardia; dizziness; first-degree heart block; headache. |
| Dose Range | Adult:Initially 5 mg twice daily, increased if necessary to 7.5 mg twice daily . |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | ANTILIPEMIC AGENTS |
| Therapeutic Class | ANTILIPEMIC AGENTS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | CHOLESTYRAMINE |
| Therapeutic Class | BILE ACID SEQUESTRANTS |
| Indications |
An effective bile acid sequesterant for use in treating type IIa hypercholesterolemia. The drug has also been used for diarrhea associated with Crohn's disease, and for pruritus associated with bi More ... |
| Caution | Constipation, abdominal discomfort, nausea, flatulence, vomiting, diarrhoea, heartburn, anorexia and indigestion. Deficiency of fat soluble vitamins may occur. |
| Dose Range | Adult and children over 12 years: Recommended starting dose is 4g once or twice daily . Maintenance dose: 8-16g daily in two divided doses. Maximum recommended daily dose: 36 grams daily in 2-4 diveded doses. Pediatric 6-12 years: 4g once to 3 ti |
| Drug Interactions | |
| Pregnancy | Since cholestyramine resin is not absorbed systemically, the drug is not expecte More ... |
| Breast Feeding |
| Active Ingredient | EZETIMIBE |
| Therapeutic Class | CHOLESTEROL ABSORPTION INHIBITORS |
| Indications | An adjunct to dietary measures and statin treatment.Reduction of total cholesterol, low-density lipoprotein (LDL)-cholesterol, and apolipoprotein B in the management of hyperlipidaemias. |
| Caution | Headache, abdominal pain, and diarrhoea. Contraindicated in patients with active liver disease or unexplained, persistent increases in serum aminotransferase (transaminase) concentrations. |
| Dose Range | 10mg once daily . Must be used in combination with a statin. |
| Drug Interactions | |
| Pregnancy | Use during pregnancy only if potential benefit to the mother outweighs the possi More ... |
| Breast Feeding |
| Active Ingredient | FENOFIBRATE |
| Therapeutic Class | FIBRIC ACID DERIVATIVES |
| Indications |
Used to reduce low-density lipoprotein (LDL)-cholesterol, total cholesterol, triglycerides, and apolipop rotein B, and to increase high-density lipoprotein (HDL)-cholesterol, in the management of Hy More ... |
| Caution | Liver function test should be carried out every 3 months.Serious muscle toxicity, including myopathy and rhabdomyolysis, has been reported in patients receiving fibric acid derivatives. Risk appears t More ... |
| Dose Range |
Adult: 67 mg three times daily or 200 mg once daily . Pediatric (4-15 years): 1 cap sule/20mg daily . |
| Drug Interactions | |
| Pregnancy | Fenofibrate is not recommended during pregnancy. |
| Breast Feeding | Fenofibrate is not recommended for lactating women. |
| Active Ingredient | GEMFIBROZIL |
| Therapeutic Class | FIBRIC ACID DERIVATIVES |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | ATORVASTATIN |
| Therapeutic Class | HMG-CoA REDUCTASE INHIBITORS |
| Indications |
Effective in the treatment of hyper-cholesterolemia and hypertrigly ceridemia. |
| Caution | Headache, diarrhoea, flatulence and mild elevations in liverenzymes. The risk of myopathy and/or rhabdomyolysis is increased when atorvastatin is taken concomitantly with cyclosporine, gemfibrozil, More ... |
| Dose Range |
Adult: Initial dose 10-20mg once daily. The dose may be adjusted at intervals of at least 4 weeks up to a maximum of 80 mg daily . See BDS supply protocols pg. 6. |
| Drug Interactions | |
| Pregnancy | Statins should be avoided in pregnancy (discontinue 3 months before attempting t More ... |
| Breast Feeding | Avoid use of atorvastatin in lactating women. |
| Active Ingredient | ROSUVASTATIN |
| Therapeutic Class | HMG-CoA REDUCTASE INHIBITORS |
| Indications | Primary hypercholesterolaemia (type IIa including heterozygous familial hypercholesterolaemia)’ mixed dyslipidaemia (type Iib), or homozygous familial hypercholesterolaemia in patients who have n More ... |
| Caution | Headache, asthenia, upper respiratory infections, gastrointestinal symptoms, and myalgia have been reported; myopathy has occurred rarely . |
| Dose Range | Adult: 5-20mg once daily . Doses may be titrated to 40mg per day in those who do not meet their lipid lowering goals on 20mg per day. Doses to be increased at intervals of at least 4 weeks. See BDS supply protocols pg. 6. |
| Drug Interactions | |
| Pregnancy | Statins should be avoided in pregnancy (discontinue 3 months before attempting t More ... |
| Breast Feeding | Avoid use of rosuvastatin in lactating women. |
| Active Ingredient | AMLODIPINE | ATORVASTATIN |
| Therapeutic Class | ANTILIPEMIC MISCELLANEOUS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | EZETIMIBE | SIMVASTATIN |
| Therapeutic Class | ANTILIPEMIC MISCELLANEOUS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |